Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
Clinical trial NCT05577182 · COMPLETED
Trial details
- NCT number
- NCT05577182
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-05
- Primary completion
- 2025-10-13
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.